Confirmation of Change in Yearend

CARSON CITY, NV, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pharmagreen Biotech, Inc. (formerly Air Transport Group Holdings, Inc.), (OTC PINKS: PHBI), is pleased to confirm the changing of its yearend to September 30th which was previously announced in the annual disclosure document filed on July 30, 2018.

On May 2, 2018, the Company completed the share exchange transaction with WFS Pharmagreen Inc. (“WFS”).  37,704,500 post roll back common shares of the Company were exchanged for all the issued and outstanding shares of “WFS”.  This transaction is being accounted for as a reverse merger with “WFS” being the accounting acquirer and the Company being the accounting acquiree.  In connection with this transaction, the Company is changing its yearend from April 30th to September 30th.

About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.

WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: AITGD) company.  WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally.  Pharmagreen’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using  low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors.  For further information on the company progress on the construction of a 60,000 square foot “Cannabis Biotech Complex” please visit

Safe Harbor Statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.

The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.


Contact Data